Table 3 A list of clinical trials of molnupiravir registered on www.ClinicalTrial.gov
From: Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
Identification no. | Title | Expected participants/dosage | Region |
|---|---|---|---|
NCT04392219 | COVID-19 First in human study to evaluate safety, tolerability, and pharmacokinetics of EIDD-2801 in healthy volunteers | 130/Single dose or two single dosages of Molnupiravir orally | United Kingdom |
NCT04405570 | A safety, tolerability and efficacy of molnupiravir (EIDD-2801) to eliminate infections virus detection in persons with COVID-19 | 204/Molnupiravir twice daily for 5Â days | United States, Multicounty |
NCT04405739 | The safety of molnupiravir (EIDD-2801) and its effect on viral shedding of SARS-CoV-2 (END-COVID) | 96/EIDD-2801 orally twice daily for 5Â days | United States, Multicounty |
NCT04746183 | AGILE (Early Phase Platform Trial for COVID-19) | 600/Molnupiravir orally 10 dosage | United Kingdom |
NCT04575584 | Efficacy and safety of molnupiravir (MK-4482) in hospitalized adult participants with COVID-19 (MK-4482-001) | 304 200Â mg or 400Â mg or 800Â mg Molnupiravir orally every 12Â h for 5Â days | Brazil, Canada, Chile, Colombia, France, Israel, Italy, Korea, Poland, Russia, South Africa, Spain, Ukraine, United States, United Kingdom |
NCT04575597 | Efficacy and safety of molnupiravir (MK-4482) in non-hospitalized adult participants with COVID-19 (MK-4482-002) | 1450/Molnupiravir administered as capsule orally every 12Â h for 5Â days | United States, Multicounty |
NCT04939428 | MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) (MOVe-AHEAD) | 1332/4 Molnupiravir 200Â mg oral capsule | Multicounty |